摘要
目的探索爱普列特对前列腺组织5α-还原酶活性及雄激素受体水平的影响。方法将40例确诊为良性前列腺增生患者随机分为两组,每组各20例。试验组服用爱普列特以及特拉唑嗪,对照组只服用特拉唑嗪。两周后全部患者行手术取前列腺组织标本,用免疫组化的方法检测40个前列腺标本中5α-还原酶的活性及雄激素受体水平。结果试验组前列腺标本中5α-还原酶染色呈弱阳性或阴性,对照组前列腺标本中5α-还原酶染色呈强阳性。40例前列腺标本雄激素受体染色均呈强阳性。结论口服爱普列特可明显抑制前列腺内5α-还原酶的活性,但对前列腺内雄激素受体水平无明显影响。
Objective To investigate the effect of epristeride on 5-alpha-reductase activity and androgen receptor levels in prostate tissue. Methods Forty patients with benign prostate hyperplasia were randomly divided into the trial group and the control group with 20 in each group. Patients in the trial group were administered oral epristeride and terazosin, while those in the control group were given just terazosin. All patients underwent trans-urethral resection of the prostate after two weeks,and then the 40 samples of prostate were tested immunohistochemicaUy for 5-alpha-reductase activities and androgen receptor levels. Results The 5-alpha-reductase in prostate tissue was not stained or lightly stained in the trial group, while it was heavily stained in the control group. The androgen receptor in prostate tissue was heavily stained in both groups. Conclusion Oral epristeride can inhibit the activity of 5-alpha-redutase in prostate tissue, but it has no obvious effect on the androgen receptor level in prostate tissue.
出处
《中国循证医学杂志》
CSCD
2008年第12期1047-1049,共3页
Chinese Journal of Evidence-based Medicine
